Literature DB >> 26263056

Inhibitive activities detection of monoamine oxidases (MAO) A and B inhibitors in human liver MAO incubations by UPLC-ESI-MS/MS.

Bo Jiang1, Shuping Li2, Wei Liu2, Yadi Yang2, Wenxia Chen2, Dandan He2, Xuemei Cheng2, Zhengtao Wang2, Wansheng Chen3, Changhong Wang4.   

Abstract

A sensitive UPLC-ESI-MS/MS method was developed for determining and screening of inhibitors of monoamine oxidase (MAO) by using mix MAO enzymes prepared from human liver. 5-Hydroxytryptamine (5-HT) and 2-phenethylamine (2-PEA) were used as substrates for MAO-A and MAO-B in incubations, and 5-hydroxyindole-3-acetic acid (5-HIAA) and phenylacetic acid (PAA) resulting from 5-HT and 2-PEA were used as markers to evaluate inhibitive activities of test compounds on MAO-A and MAO-B. Proper separation was achieved for positive multiple reaction monitoring of 5-HIAA (m/z 192.1→146.1) and negative multiple reaction monitoring PAA (m/z 135.0→91.0) via isocratic elution (0.1% fromic acid:acetonitrile=60:40) on a HSS T3 column following a simple precipitation of proteins for sample treatment. The relative standard deviations of intra- and inter-day precisions were ranged from 1.74% to 6.76% and 0.77% to 9.35%. The mean accuracies for the quality control samples were 101.37±6.60% and 101.39±2.85%, respectively. This method exhibited characteristics of small total reaction volume (100μl), short analysis time (3.5min), highly sensitivity, low cost and without matrix effect (103.56±2.33% to 112.63±8.57% for 5-HIAA and 105.68±8.75% to 112.76±4.67% for PAA). The developed method was successfully applied for detection of the MAO-A and MAO-B inhibitive activities by model drugs, including pargyline, clorgyline, as well as β-carboline alkaloids from Peganum harmala.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  5-HIAA; Inhibitor; MAO-A; MAO-B; PAA; UPLC–ESI MS/MS

Mesh:

Substances:

Year:  2015        PMID: 26263056     DOI: 10.1016/j.jpba.2015.07.029

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  5 in total

1.  Exposure Characteristics of the Analogous β-Carboline Alkaloids Harmaline and Harmine Based on the Efflux Transporter of Multidrug Resistance Protein 2.

Authors:  Shuping Li; Yunpeng Zhang; Gang Deng; Yuwen Wang; Shenglan Qi; Xuemei Cheng; Yueming Ma; Yan Xie; Changhong Wang
Journal:  Front Pharmacol       Date:  2017-08-21       Impact factor: 5.810

2.  Using Molecular Docking Analysis to Discovery Dregea sinensis Hemsl. Potential Mechanism of Anticancer, Antidepression, and Immunoregulation.

Authors:  Xiujie Liu; Yu Shi; Yulin Deng; Rongji Dai
Journal:  Pharmacogn Mag       Date:  2017-07-19       Impact factor: 1.085

3.  Time- and NADPH-Dependent Inhibition on CYP3A by Gomisin A and the Pharmacokinetic Interactions between Gomisin A and Cyclophosphamide in Rats.

Authors:  Jianxiu Zhai; Feng Zhang; Shouhong Gao; Li Chen; Ge Feng; Jun Yin; Wansheng Chen
Journal:  Molecules       Date:  2017-08-08       Impact factor: 4.411

4.  Potential Pharmacokinetic Drug⁻Drug Interaction Between Harmine, a Cholinesterase Inhibitor, and Memantine, a Non-Competitive N-Methyl-d-Aspartate Receptor Antagonist.

Authors:  Yunpeng Zhang; Shuping Li; Youxu Wang; Gang Deng; Ning Cao; Chao Wu; Wenzheng Ding; Yuwen Wang; Xuemei Cheng; Changhong Wang
Journal:  Molecules       Date:  2019-04-11       Impact factor: 4.411

Review 5.  Peganum spp.: A Comprehensive Review on Bioactivities and Health-Enhancing Effects and Their Potential for the Formulation of Functional Foods and Pharmaceutical Drugs.

Authors:  Javad Sharifi-Rad; Cristina Quispe; Jesús Herrera-Bravo; Prabhakar Semwal; Sakshi Painuli; Beraat Özçelik; Furkan Ediz Hacıhasanoğlu; Shabnum Shaheen; Surjit Sen; Krishnendu Acharya; Marjan Amirian; Carla Marina Salgado Castillo; María Dolores López; Mauricio Schoebitz; Miquel Martorell; Tamar Goloshvili; Ahmed Al-Harrasi; Ahmed Al-Rawahi; Manoj Kumar; Hafiz Ansar Rasul Suleria; William C Cho
Journal:  Oxid Med Cell Longev       Date:  2021-06-27       Impact factor: 6.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.